Spend $50 or More, Get Free USA Shipping Under 10lbs

0

Your Cart is Empty

Solaray

Solaray Valerian Root 470 mg 100 caps

  |  
Free USA Shipping Over $50
USA Flat Rate Shipping Under $50
6 items left

Solaray Valerian Root 470 mg

Valerian in a perennial flowering plant native to Europe and Asia who's root has a variety of uses. People often use Valerian Root to treat insomnia, anxiety, and even hot flashes in menopausal women. Solaray's Valerian root contains 470mg of whole root valerian root per capsule and is 100% Vegan friendly and Non-GMO

Solaray Valerian Root Highlights

  • Valerian Root is Often Used to Treat Insomnia
  • Many Use Valerian Root for Anxiety
  • Studies Have Shown Valerian Root Reduced the Severity of Hot Flashes
  • 470mg Per Capsule
  • Whole Root Valerian Root
  • 100% Vegan
  • Non-GMO

What is Valerian Root Used For?

  • Sleep Disorders
  • Anxiety
  • Psychological Stress
  • Hot Flashes

Is Valerian Root Good for Anxiety?

Valerian Root is a common ingredient in many dietary supplements for sleep disorders or anxiety. Valerian Root has also been used for centuries as an herbal remedy. 

Directions

Use only as directed. Take one VegCap daily with a meal or glass of water.

Solaray Valerian Root Supplement Facts & Ingredients

Serving Size: 1 Vegetable Capsule

Valerian (Valeriana officinalis) (root) 470mg

*Daily Value Not Established

Other Ingredients: Vegetable cellulose capsule

Warnings

Do not use if safety seal is broken or missing. Keep out of reach of children. Keep your licensed health care practitioner informed when using this product, especially if you are taking a prescription medication. Store in a cool, dry place.

References

Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005–1012. doi:10.1016/j.amjmed.2006.02.026

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394901/

Barton DL, Atherton PJ, Bauer BA, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. 2011;9(1):24–31. doi:10.1016/j.suponc.2010.12.008

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052692/

Subscribe